Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
NS 309 is a positive modulator of small- and intermediate- conductance Ca2+-activated K+ channels (KCa2 and KCa3.1 channels); increases Ca2+ sensitivity. Displays no activity at BK channels.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 231.04. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.33 mL||21.64 mL||43.28 mL|
|5 mM||0.87 mL||4.33 mL||8.66 mL|
|10 mM||0.43 mL||2.16 mL||4.33 mL|
|50 mM||0.09 mL||0.43 mL||0.87 mL|
References are publications that support the biological activity of the product.
Grgic et al (2009) Endothelial Ca2+-activated K+ channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery. Br.J.Pharmacol. 157 509 PMID: 19302590
Strobaek et al (2004) Activation of human IK and SK Ca2+-activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Biochim.Biophys.Acta 1665 1 PMID: 15471565
Morimura et al (2006) Voltage-dependent Ca2+-channel block by openers of intermediate and small conductance Ca2+-activated K+ channels in urinary bladder smooth muscle cells. J.Pharm.Sci. 100 237 PMID: 16518073
If you know of a relevant reference for NS 309, please let us know.
View all Calcium-Activated Potassium (KCa) Channel Modulators
Keywords: NS 309, NS 309 supplier, NS309, Ca2+-activated, potassium, K+, KCa, channels, activators, positive, modulators, small, intermediate, conductance, SK, IK, KCa2, KCa3, Ca2+-Activated, Potassium, Channels, 3895, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for NS 309 include:
Wong et al (2014) Sex differences in endothelial function in porcine coronary arteries: a role for H2O2 and gap junctions?. Br J Pharmacol 171 2751 PMID: 24467384
D'Alessandro et al (2013) KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death Dis 4 e773 PMID: 23949222
Oliveira et al (2010) Altered expression and function of small-conductance (SK) Ca(2+)-activated K+ channels in PilC-treated epileptic rats. Brain Res 1348 187 PMID: 20553876
Hipólito et al (2015) In vivo activation of the SK channel in the spinal cord reduces the NMDA receptor antagonist dose needed to produce antinociception in an inflammatory pain model. Pain 156 849 PMID: 25734988
Hakim et al (2018) Electrical dynamics of isolated cerebral and skeletal muscle endothelial tubes: Differential roles of G-protein-coupled receptors and K+ channels. Pharmacol Res Perspect 6 e00391 PMID: 29636977
Zhang et al (2015) Molecular overlap in the regulation of SK channels by small molecules and phosphoinositides. Neurochem Int 1 e1500008 PMID: 26366439
Do you know of a great paper that uses NS 309 from Tocris? Please let us know.
Average Rating: 5 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
NS 309 is a potent Kca channel activator. I worked with 10,20,30,40,50,80,100 micrograms dissolved in DMSO. The product worked nicely in experimental conditions and would suggest to others researching Kca channel activation.
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.